Taking a detour

Anna Dart

DOI: https://doi.org/10.1038/s41568-024-00707-5

IF: 78.5

2024-05-17

Nature Reviews Cancer

Abstract:Kong et al. have now shown that Knudson's two-hit hypothesis can be circumvented through the actions of the glycolytic metabolite methylglyoxal, which transiently inactivates the tumour-suppressive functions of BRCA2 leading to episodic mutagenesis and cancer genome evolution.

oncology

What problem does this paper attempt to address?

A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2

Li Ren Kong,Komal Gupta,Andy Jialun Wu,David Perera,Roland Ivanyi-Nagy,Syed Moiz Ahmed,Tuan Zea Tan,Shawn Lu-Wen Tan,Alessandra Fuddin,Elayanambi Sundaramoorthy,Grace Shiqing Goh,Regina Tong Xin Wong,Ana S.H. Costa,Callum Oddy,Hannan Wong,C. Pawan K. Patro,Yun Suen Kho,Xiao Zi Huang,Joan Choo,Mona Shehata,Soo Chin Lee,Boon Cher Goh,Christian Frezza,Jason J. Pitt,Ashok R. Venkitaraman

DOI: https://doi.org/10.1016/j.cell.2024.03.006

IF: 64.5

2024-04-26

Cell

Abstract:Cells carrying a monoallelic germline BRCA2 mutation can bypass Knudson's "two-hit" requirement to initiate tumorigenesis when the glycolytic metabolite methylglyoxal transiently disables BRCA2 function. Metabolic bypass of tumor suppressor activity may link metabolic reprogramming, metabolic disorders, or diet to early steps in carcinogenesis.

cell biology,biochemistry & molecular biology
A glycolytic metabolite that drives BRCA2 haploinsufficiency

Peng Jiang

DOI: https://doi.org/10.1016/j.cell.2024.03.028

IF: 64.5

2024-04-26

Cell

Abstract:Many types of tumor cells alter metabolic pathways to meet their energy and biosynthetic demands for proliferation or stress adaptation. In this issue of Cell, Kong et al. find that the glycolytic metabolite methylglyoxal causes cancer-associated mutant single-base substitution features by inducing BRCA2 proteolysis, leading to functional haploinsufficiency of BRCA2.

cell biology,biochemistry & molecular biology
Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability

Neil Johnson

DOI: https://doi.org/10.1172/jci179325

IF: 19.456

2024-04-02

Journal of Clinical Investigation

Abstract:While breast cancer 2 ( BRCA2 ) loss of heterozygosity (LOH) promotes cancer initiation, it can also induce death in nontransformed cells. In contrast, mismatch repair gene mutL homolog 1 ( MLH1 ) is a tumor-suppressor gene that protects cells from cancer development through repairing mismatched base pairs during DNA mismatch repair (MMR). Sengodan et al., in this issue of the JCI , reveal an interplay between the 2 genes: MLH1 promoted the survival of BRCA2-deficient cells independently of its MMR function. MLH1 protected replication forks from degradation, while also resolving R-loops, thereby reducing genomic instability. Moreover, MLH1 expression was regulated directly by estrogen, shedding light into the hormone-responsive nature of many BRCA2 mutant breast cancers. These results provide important insight into the genetics that drive the initiation of BRCA2 -mutated breast cancers.

medicine, research & experimental
In my end is my beginning: control of end resection and DSBR pathway ‘choice’ by cyclin-dependent kinases

Ralph Scully,Anyong Xie

DOI: https://doi.org/10.1038/sj.onc.1208609

IF: 8.756

2005-01-01

Oncogene

Abstract:The genome is constantly subjected to chemical alterations that have the potential to cause genetic mutation, chromosomal rearrangements and, in the case of multicellular organisms, cancer. Particular vulnerability exists during DNA replication, when the two DNA strands of a chromosome separate to form templates for the synthesis of sister chromatids. Attempted replication across a damaged or nicked DNA template can result in the formation of a double-strand break (DSB), arguably the most dangerous of DNA lesions. DSBs can also arise directly at any cell cycle stage following exposure to ionizing radiation or radiomimetic agents. To combat these recurrent threats of genomic instability, numerous distinct enzyme systems have evolved that sense DNA damage and coordinate its repair. Part of this coordination involves the activation of signal transduction cascades that target repair proteins, trigger DNA damage-dependent cell cycle checkpoints and profoundly affect chromatin neighboring a DSB. Here, we discuss current models of how lesion processing itself helps to coordinate these signals in dividing cells. Recent evidence in yeast of a role for cyclin-dependent kinases in DNA end resection suggests a possible solution to the long-standing puzzle of how DSBR pathway ‘choice’ is regulated through the cell cycle.
DNA repair, gap suppression, or fork protection: BRCA2 needs a break!

Diego Dibitetto,Sven Rottenberg

DOI: https://doi.org/10.1016/j.molcel.2023.12.026

IF: 16

2024-02-01

Molecular Cell

Abstract:In this issue of Molecular Cell, Lim et al.<sup>1</sup> reveal new insights into the distinct roles of BRCA2 in coping with DNA breaks, highlighting homologous recombination as the pivotal function that affects tumorigenesis and therapy response.

cell biology,biochemistry & molecular biology
Checkpoint adaptation in recombination-deficient cells drives aneuploidy and resistance to genotoxic agents

Olga Vydzhak,Katharina Bender,Julia Klermund,Anke Busch,Stefanie Reimann,Brian Luke

DOI: https://doi.org/10.1016/j.dnarep.2020.102939

Abstract:Human cancers frequently harbour mutations in DNA repair genes, rendering the use of DNA damaging agents as an effective therapeutic intervention. As therapy-resistant cells often arise, it is important to better understand the molecular pathways that drive resistance in order to facilitate the eventual targeting of such processes. We employ recombination-defective diploid yeast as a model to demonstrate that, in response to genotoxic challenges, nearly all cells eventually undergo checkpoint adaptation, resulting in the generation of aneuploid cells with whole chromosome losses that have acquired resistance to the initial genotoxic challenge. We demonstrate that adaptation inhibition, either pharmacologically, or genetically, drastically reduces the occurrence of resistant cells. Additionally, the aneuploid phenotypes of the resistant cells can be specifically targeted to induce cytotoxicity. We provide evidence that TORC1 inhibition with rapamycin, in combination with DNA damaging agents, can prevent both checkpoint adaptation and the continued growth of aneuploid resistant cells.
A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance

Enol Álvarez-González,Luisa María Sierra

DOI: https://doi.org/10.3390/ijms25169054

IF: 5.6

2024-08-22

International Journal of Molecular Sciences

Abstract:Metabolic changes involving the tricarboxylic acid (TCA) cycle have been linked to different non-metabolic cell processes. Among them, apart from cancer and immunity, emerges the DNA damage response (DDR) and specifically DNA damage repair. The oncometabolites succinate, fumarate and 2-hydroxyglutarate (2HG) increase reactive oxygen species levels and create pseudohypoxia conditions that induce DNA damage and/or inhibit DNA repair. Additionally, by influencing DDR modulation, they establish direct relationships with DNA repair on at least four different pathways. The AlkB pathway deals with the removal of N-alkylation DNA and RNA damage that is inhibited by fumarate and 2HG. The MGMT pathway acts in the removal of O-alkylation DNA damage, and it is inhibited by the silencing of the MGMT gene promoter by 2HG and succinate. The other two pathways deal with the repair of double-strand breaks (DSBs) but with opposite effects: the FH pathway, which uses fumarate to help with the repair of this damage, and the chromatin remodeling pathway, in which oncometabolites inhibit its repair by impairing the homologous recombination repair (HRR) system. Since oncometabolites inhibit DNA repair, their removal from tumor cells will not always generate a positive response in cancer therapy. In fact, their presence contributes to longer survival and/or sensitization against tumor therapy in some cancer patients.

biochemistry & molecular biology,chemistry, multidisciplinary
BRCA1-associated Tumorigenesis: What Have We Learned from Knockout Mice?

Steven G Brodie,Chu-Xia Deng

DOI: https://doi.org/10.1016/s0168-9525(01)02451-9

IF: 11.4

2001-01-01

Trends in Genetics

Abstract:A series of allelic mutations in the tumor suppressor Brca1 have been created to study mechanisms underlying BRCA1-associated tumorigenesis. Brca1 is essential in maintaining genome integrity through its involvement in DNA damage repair, G(2)-M cell-cycle checkpoint and centrosome duplication. The loss of Brca1 is not sufficient for malignant transformation, rather, it triggers multiple genetic alterations, including the inactivation of p53 and activation of a number of oncogenes, that ultimately result in mammary tumorigenesis.
Linking Cancer Metabolism to DNA Repair and Accelerated Senescence

E. Labay,S. Kozmin,Satoe Takahashi,R. Weichselbaum,S. Kron,Noumaan A. Shamsi,O. Ulanovskaya,Ding Wu,E. Efimova

DOI: https://doi.org/10.1158/1541-7786.MCR-15-0263

2015-11-04

Molecular Cancer Research

Abstract:Conventional wisdom ascribes metabolic reprogramming in cancer to meeting increased demands for intermediates to support rapid proliferation. Prior models have proposed benefits toward cell survival, immortality, and stress resistance, although the recent discovery of oncometabolites has shifted attention to chromatin targets affecting gene expression. To explore further effects of cancer metabolism and epigenetic deregulation, DNA repair kinetics were examined in cells treated with metabolic intermediates, oncometabolites, and/or metabolic inhibitors by tracking resolution of double-strand breaks (DSB) in irradiated MCF7 breast cancer cells. Disrupting cancer metabolism revealed roles for both glycolysis and glutaminolysis in promoting DSB repair and preventing accelerated senescence after irradiation. Targeting pathways common to glycolysis and glutaminolysis uncovered opposing effects of the hexosamine biosynthetic pathway (HBP) and tricarboxylic acid (TCA) cycle. Treating cells with the HBP metabolite N-acetylglucosamine (GlcNAc) or augmenting protein O-GlcNAcylation with small molecules or RNAi targeting O-GlcNAcase each enhanced DSB repair, while targeting O-GlcNAc transferase reversed GlcNAc's effects. Opposing the HBP, TCA metabolites including α-ketoglutarate blocked DSB resolution. Strikingly, DNA repair could be restored by the oncometabolite 2-hydroxyglutarate (2-HG). Targeting downstream effectors of histone methylation and demethylation implicated the PRC1/2 polycomb complexes as the ultimate targets for metabolic regulation, reflecting known roles for Polycomb group proteins in nonhomologous end-joining DSB repair. Our findings that epigenetic effects of cancer metabolic reprogramming may promote DNA repair provide a molecular mechanism by which deregulation of metabolism may not only support cell growth but also maintain cell immortality, drive therapeutic resistance, and promote genomic instability. Implications: By defining a pathway from deregulated metabolism to enhanced DNA damage response in cancer, these data provide a rationale for targeting downstream epigenetic effects of metabolic reprogramming to block cancer cell immortality and overcome resistance to genotoxic stress. Mol Cancer Res; 14(2); 173–84. ©2015 AACR.

Medicine,Biology
Serendipity Strikes: How Pursuing Novel Hypotheses Shifted the Paradigm Regarding the Genetic Basis of Colorectal Cancer and Changed Cancer Therapy

C Richard Boland,Minoru Koi,Mary T Hawn,John M Carethers,Matthew B Yurgelun

DOI: https://doi.org/10.1007/s10620-023-08006-z

Abstract:In this installment of the "Paradigm Shifts in Perspective" series, the authors, all scientists who have been involved in colorectal cancer (CRC) research for most or all of their careers, have watched the field develop from early pathological descriptions of tumor formation to the current understanding of tumor pathogenesis that informs personalized therapies. We outline how our understanding of the pathogenetic basis of CRC began with seemingly isolated discoveries-initially with the mutations in RAS and the APC gene, the latter of which was initially found in the context of intestinal polyposis, to the more complex process of multistep carcinogenesis, to the chase for tumor suppressor genes, which led to the unexpected discovery of microsatellite instability (MSI). These discoveries enabled the authors to better understand how the DNA mismatch repair (MMR) system not only recognizes DNA damage but also responds to damage by DNA repair or by triggering apoptosis in the injured cell. This work served, in part, to link the earlier findings on the pathogenesis of CRC to the development of immune checkpoint inhibitors, which has been transformative-and curative-for certain types of CRCs and other cancers as well. These discoveries also highlight the circuitous routes that scientific progress takes, which can include thoughtful hypothesis testing and at other times recognizing the importance of seemingly serendipitous observations that substantially change the flow and direction of the discovery process. What has happened over the past 37 years was not predictable when this journey began, but it does speak to the power of careful scientific experimentation, following the facts, perseverance in the face of opposition, and the willingness to think outside of established paradigms.
Understanding the interplay between dNTP metabolism and genome stability in cancer

Miriam Yagüe-Capilla,Sean G Rudd

DOI: https://doi.org/10.1242/dmm.050775

2024-08-01

Abstract:The size and composition of the intracellular DNA precursor pool is integral to the maintenance of genome stability, and this relationship is fundamental to our understanding of cancer. Key aspects of carcinogenesis, including elevated mutation rates and induction of certain types of DNA damage in cancer cells, can be linked to disturbances in deoxynucleoside triphosphate (dNTP) pools. Furthermore, our approaches to treat cancer heavily exploit the metabolic interplay between the DNA and the dNTP pool, with a long-standing example being the use of antimetabolite-based cancer therapies, and this strategy continues to show promise with the development of new targeted therapies. In this Review, we compile the current knowledge on both the causes and consequences of dNTP pool perturbations in cancer cells, together with their impact on genome stability. We outline several outstanding questions remaining in the field, such as the role of dNTP catabolism in genome stability and the consequences of dNTP pool expansion. Importantly, we detail how our mechanistic understanding of these processes can be utilised with the aim of providing better informed treatment options to patients with cancer.
Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells

Bhupender Kumar,Rameshwar N. K. Bamezai

DOI: https://doi.org/10.1007/s11033-015-3876-8

IF: 2.7422

2015-04-04

Molecular Biology Reports

Abstract:Pyruvate kinase M2, an important metabolic enzyme, promotes aerobic glycolysis (Warburg effect) to facilitate cancer cell proliferation. Unravelling the status of this important glycolytic pathway enzyme under sub-lethal doses of etoposide, a commonly used anti-proliferative genotoxic drug to induce mild/moderate DNA damage in HeLa cells as a model system and discern its effect on: PKM2 expression, phosphorylation, dimer: tetramer ratio, activity and associated effects, was pertinent. Protein expression and phosphorylation of PKM2 from HeLa cells was estimated using Western blotting. Same protein lysate was also used to estimate total pyruvate kinase activity and the total dimer: tetramer content evaluated using glycerol gradient ultra-centrifugation. Intracellular PEP was estimated manually using standard curve; while NADPH was assessed by NADPH estimation kit. Unpaired t test and two-way-ANOVA was used for statistical analysis. A relative decrease in PKM2 expression and a subsequent dose and time dependent increase in Y105-phosphorylation were observed. A concomitant increase in PKM2 dimer content and Y105-phosphorylation responsible for reduced PKM2 activity promoted PEP accumulation and NADPH production, representing increased metabolic flux into PPP, a feature that favours cancer cells. It was apparent that the sub-lethal doses of etoposide induced inadequate damage to DNA in cancer cells in culture promoted pro-survival conditions due to Y105-phosphorylation of PKM2, its stable dimerization and inactivation, a unique association not known earlier, indicating what might happen in tumour revivals or recurrences.

biochemistry & molecular biology
Cancer-epigenetics comes of age

Peter A Jones,Peter W Laird

DOI: https://doi.org/10.1038/5947

IF: 30.8

1999-02-01

Nature Genetics

Abstract:The discovery of numerous hypermethylated promoters of tumour–suppressor genes, along with a better understanding of gene–silencing mechanisms, has moved DNA methylation from obscurity to recognition as an alternative mechanism of tumour–suppressor inactivation in cancer. Epigenetic events can also facilitate genetic damage, as illustrated by the increased mutagenicity of 5–methylcytosine and the silencing of the MLH1 mismatch repair gene by DNA methylation in colorectal tumours. We review here current mechanistic understanding of the role of DNA methylation in malignant transformation, and suggest Knudson's two–hit hypothesis should now be expanded to include epigenetic mechanisms of gene inactivation.

genetics & heredity
Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma

Lucy F Stead,Roel G W Verhaak

DOI: https://doi.org/10.1016/j.ccell.2019.03.009

IF: 50.3

2019-04-15

Cancer Cell

Abstract:Using longitudinal molecular profiling, Körber et al. propose in this issue of Cancer Cell that IDH-wild-type glioblastomas initiate years pre-diagnosis with chromosome-level alterations that drive cell proliferation but require survival-promoting mutations, commonly in the TERT promoter, to form a detectable tumor. Multiple subclones drive disease progression, creating a therapeutic challenge.
A CINful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction

Daniel Bronder,Samuel F Bakhoum

DOI: https://doi.org/10.15252/emmm.202012017

2020-03-06

Abstract:Oncogene-addicted tumors present a valuable target for therapeutic intervention and an opportunity to achieve a wide therapeutic window. Nonetheless, resistance to targeted therapies is frequently observed and it arises through multiple mechanisms, including mutations in the target gene. Chromosomal instability, a defining feature of human cancer, has been linked to targeted therapy resistance, but the mechanism underlying this association is poorly understood. In the current issue of EMBO Molecular Medicine, Salgueiro et al show that chromosomal instability can lead to the generation of alternative oncogenic drivers, thereby providing the ability for cancer cells to overcome the oncogene withdrawal bottleneck. Importantly, this study shows that, by generating de novo genomic diversity, chromosomal instability serves as an adaptive response to therapeutic insult.
SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity

Ming Tang,Guofang Chen,Bo Tu,Zhiyi Hu,Yujia Huang,Christopher C DuFort,Xiaoping Wan,Zhiyong Mao,Yongzhong Liu,Wei-Guo Zhu,Wen Lu

DOI: https://doi.org/10.1126/sciadv.ade6624

2023-06-16

Abstract:DNA damage repair (DDR) is a double-edged sword with different roles in cancer susceptibility and drug resistance. Recent studies suggest that DDR inhibitors affect immune surveillance. However, this phenomenon is poorly understood. We report that methyltransferase SMYD2 plays an essential role in nonhomologous end joining repair (NHEJ), driving tumor cells adaptive to radiotherapy. Mechanically, in response to DNA damage, SMYD2 is mobilized onto chromatin and methylates Ku70 at lysine-74, lysine-516, and lysine-539, leading to increased recruitment of Ku70/Ku80/DNA-PKcs complex. Knockdown of SMYD2 or its inhibitor AZ505 results in persistent DNA damage and improper repair, which sequentially leads to accumulation of cytosolic DNA, and activation of cGAS-STING pathway and triggers antitumor immunity via infiltration and activation of cytotoxic CD8+ T cells. Our study reveals an unidentified role of SMYD2 in regulating NHEJ pathway and innate immune responses, suggesting that SMYD2 is a promising therapeutic target for cancer treatment.
Abstract 4565: Reckless mitotic entry as a chemosensitization approach for alkylating agents

Fengchao Lang,James A. Cornwell,Karambir Kaur,Mirit I. Aladjem,Michael Aregger,Steven D. Cappell,Chunzhang Yang

DOI: https://doi.org/10.1158/1538-7445.am2024-4565

IF: 11.2

2024-03-23

Cancer Research

Abstract:The cell cycle is tightly regulated by checkpoints, playing a vital role in controlling its progression and timing. Cancer cells exploit the G2/M checkpoint, which serves as a resistance mechanism against genotoxic anti-cancer treatments, allowing for DNA repair prior to cell division. Therefore, manipulating cell cycle timing has emerged as a potential strategy to augment the effectiveness of DNA damage-based therapies such as alkylating agents and radiation. In this study, we conducted a forward genome scale CRISPR/Cas9 chemogenomic screening with repeated exposure to the alkylating agent temozolomide (TMZ) to investigate the mechanisms underlying tumor cell survival under genotoxic stress. Our findings revealed that canonical DNA repair pathways, including ATM/Fanconi and mismatch repair, determine cell fate under genotoxic stress. Notably, we identified the critical role of the membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase, known as Myt1 (encoded by PKMYT1), in ensuring cell survival. Analysis on patient cohort demonstrated that PKMYT1 is not only highly presented in malignancy, but also predisposes an unfavorable disease outcome. Genetic depletion of PKMYT1 led to overwhelming TMZ-induced cytotoxicity in cancer cells. Isobologram analysis demonstrated potent drug synergy between TMZ and other clinically used alkylating agents, such as carmustine, busulfan, and dacarbazine, when combined with a novel Myt1 kinase inhibitor, RP-6306. Mechanistically, inhibiting Myt1 forced G2/M-arrested cells into an unscheduled transition to the mitotic phase without complete resolution of DNA damage, as indicated by a substantial increase in γH2AX-positive cells in mitosis. Moreover, RP-6306 dramatically altered cell cycle timing, reducing the threshold time for mitotic entry. This forced entry into mitosis, along with persistent DNA damage, resulted in severe mitotic abnormalities, including unaligned and partially condensed chromosomes, lagging chromosomes, chromosome bridges, and multipolar spindles. Ultimately, these aberrations led to mitotic exit with substantial apoptosis. Importantly, preclinical animal studies demonstrated that the combination regimen involving TMZ and RP-6306 prolonged the overall survival of glioma-bearing mice. Collectively, our findings highlight the potential of targeting cell cycle timing through Myt1 inhibition as an effective strategy to enhance the efficacy of current standard cancer therapies, potentially leading to improved disease outcomes. Citation Format: Fengchao Lang, James A. Cornwell, Karambir Kaur, Mirit I. Aladjem, Michael Aregger, Steven D. Cappell, Chunzhang Yang. Reckless mitotic entry as a chemosensitization approach for alkylating agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4565.

oncology
Targeting DNA damage response pathways in cancer

Florian J. Groelly,Matthew Fawkes,Rebecca A. Dagg,Andrew N. Blackford,Madalena Tarsounas

DOI: https://doi.org/10.1038/s41568-022-00535-5

IF: 78.5

2022-12-06

Nature Reviews Cancer

Abstract:Cells have evolved a complex network of biochemical pathways, collectively known as the DNA damage response (DDR), to prevent detrimental mutations from being passed on to their progeny. The DDR coordinates DNA repair with cell-cycle checkpoint activation and other global cellular responses. Genes encoding DDR factors are frequently mutated in cancer, causing genomic instability, an intrinsic feature of many tumours that underlies their ability to grow, metastasize and respond to treatments that inflict DNA damage (such as radiotherapy). One instance where we have greater insight into how genetic DDR abrogation impacts on therapy responses is in tumours with mutated BRCA1 or BRCA2 . Due to compromised homologous recombination DNA repair, these tumours rely on alternative repair mechanisms and are susceptible to chemical inhibitors of poly(ADP-ribose) polymerase (PARP), which specifically kill homologous recombination-deficient cancer cells, and have become a paradigm for targeted cancer therapy. It is now clear that many other synthetic-lethal relationships exist between DDR genes. Crucially, some of these interactions could be exploited in the clinic to target tumours that become resistant to PARP inhibition. In this Review, we discuss state-of-the-art strategies for DDR inactivation using small-molecule inhibitors and highlight those compounds currently being evaluated in the clinic.

oncology
Somatic Mutation of the Cohesin Complex Subunit Confers Therapeutic Vulnerabilities in Cancer.

Yunhua Liu,Hanchen Xu,Kevin Van der Jeught,Yujing Li,Sheng Liu,Lu Zhang,Yuanzhang Fang,Xinna Zhang,Milan Radovich,Bryan P Schneider,Xiaoming He,Cheng Huang,Chi Zhang,Jun Wan,Guang Ji,Xiongbin Lu

DOI: https://doi.org/10.1172/jci98727

2018-01-01

Abstract:A synthetic lethality-based strategy has been developed to identify therapeutic targets in cancer harboring tumor-suppressor gene mutations, as exemplified by the effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are less reliable due to the fact that such genes usually do not perform fundamental or indispensable functions in the cell. Here, we developed an approach to identifying the "essential lethality" arising from these mutated/deleted essential genes, which are largely tolerated in cancer cells due to genetic redundancy. We uncovered the cohesion subunit SA1 as a putative synthetic-essential target in cancers carrying inactivating mutations of its paralog, SA2. In SA2-deficient Ewing sarcoma and bladder cancer, further depletion of SA1 profoundly and specifically suppressed cancer cell proliferation, survival, and tumorigenic potential. Mechanistically, inhibition of SA1 in the SA2-mutated cells led to premature chromatid separation, dramatic extension of mitotic duration, and consequently, lethal failure of cell division. More importantly, depletion of SA1 rendered those SA2-mutated cells more susceptible to DNA damage, especially double-strand breaks (DSBs), due to reduced functionality of DNA repair. Furthermore, inhibition of SA1 sensitized the SA2-deficient cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with SA2-deficient tumors.
Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents

Fengchao Lang,James A Cornwell,Karambir Kaur,Omar Elmogazy,Wei Zhang,Meili Zhang,Hua Song,Zhonghe Sun,Xiaolin Wu,Mirit I Aladjem,Michael Aregger,Steven D Cappell,Chunzhang Yang

DOI: https://doi.org/10.1093/neuonc/noad252

2024-06-03

Abstract:Background: The cell cycle is tightly regulated by checkpoints, which play a vital role in controlling its progression and timing. Cancer cells exploit the G2/M checkpoint, which serves as a resistance mechanism against genotoxic anticancer treatments, allowing for DNA repair prior to cell division. Manipulating cell cycle timing has emerged as a potential strategy to augment the effectiveness of DNA damage-based therapies. Methods: In this study, we conducted a forward genome-wide CRISPR/Cas9 screening with repeated exposure to the alkylating agent temozolomide (TMZ) to investigate the mechanisms underlying tumor cell survival under genotoxic stress. Results: Our findings revealed that canonical DNA repair pathways, including the Ataxia-telangiectasia mutated (ATM)/Fanconi and mismatch repair, determine cell fate under genotoxic stress. Notably, we identified the critical role of PKMYT1, in ensuring cell survival. Depletion of PKMYT1 led to overwhelming TMZ-induced cytotoxicity in cancer cells. Isobologram analysis demonstrated potent drug synergy between alkylating agents and a Myt1 kinase inhibitor, RP-6306. Mechanistically, inhibiting Myt1 forced G2/M-arrested cells into an unscheduled transition to the mitotic phase without complete resolution of DNA damage. This forced entry into mitosis, along with persistent DNA damage, resulted in severe mitotic abnormalities. Ultimately, these aberrations led to mitotic exit with substantial apoptosis. Preclinical animal studies demonstrated that the combination regimen involving TMZ and RP-6306 prolonged the overall survival of glioma-bearing mice. Conclusions: Collectively, our findings highlight the potential of targeting cell cycle timing through Myt1 inhibition as an effective strategy to enhance the efficacy of current standard cancer therapies, potentially leading to improved disease outcomes.

Taking a detour

A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2

A glycolytic metabolite that drives BRCA2 haploinsufficiency

Surviving without BRCA2: MLH1 gets R-looped in to curtail genomic instability

In my end is my beginning: control of end resection and DSBR pathway ‘choice’ by cyclin-dependent kinases

DNA repair, gap suppression, or fork protection: BRCA2 needs a break!

Checkpoint adaptation in recombination-deficient cells drives aneuploidy and resistance to genotoxic agents

A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance

BRCA1-associated Tumorigenesis: What Have We Learned from Knockout Mice?

Linking Cancer Metabolism to DNA Repair and Accelerated Senescence

Serendipity Strikes: How Pursuing Novel Hypotheses Shifted the Paradigm Regarding the Genetic Basis of Colorectal Cancer and Changed Cancer Therapy

Understanding the interplay between dNTP metabolism and genome stability in cancer

Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells

Cancer-epigenetics comes of age

Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma

A CINful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction

SMYD2 inhibition-mediated hypomethylation of Ku70 contributes to impaired nonhomologous end joining repair and antitumor immunity

Abstract 4565: Reckless mitotic entry as a chemosensitization approach for alkylating agents

Targeting DNA damage response pathways in cancer

Somatic Mutation of the Cohesin Complex Subunit Confers Therapeutic Vulnerabilities in Cancer.

Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents